Dei Cas A, Spigoni V, Cito M, Aldigeri R, Ridolfi V, Marchesi E, Marina M, Derlindati E, Aloe R, Bonadonna RC, Zavaroni I
Research Background DSIP has been investigated in preclinical models for its proposed neuromodulatory roles, including effects on sleep architecture, stress response, and the hypothalamic-pituitary axis
While it shares the same active ingredient as some GLP-1 weight loss medications, Ozempic is only approved for treating type 2 diabetes, not weight loss
These perspectives are part of a wider dialogue, but they dont reflect the majority experience shared in threads focused on product results
Life-changing for many people who had struggled with obesity for years